Nplate REMS Precludes Need For Medicare Coverage Restrictions – Amgen
Executive Summary
Amgen's platelet producer Nplate (romiplostim) does not need coverage restrictions from Medicare to ensure its safe use because it is already the subject of an FDA-mandated Risk Evaluation and Mitigation Strategy, the company told CMS in recent comments
You may also be interested in...
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
Amgen’s Nplate Has First Mandatory Patient Registration Under REMS
The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients